|
๐
|
Sofosbuvir for previously untreated chronic hepatitis C infection.
24 auth.
E. Lawitz,
A. Mangia,
D. Wyles,
M. Rodriฬguez-Torres,
T. Hassanein,
S. Gordon,
M. Schultz,
Mitchell N. Davis,
Z. Kayali,
K. Reddy,
...
I. Jacobson,
K. Kowdley,
L. Nyberg,
G. Subramanian,
R. Hyland,
S. Arterburn,
D. Jiang,
J. McNally,
D. Brainard,
W. Symonds,
J. Mchutchison,
A. Sheikh,
Z. Younossi,
E. Gane
|
10 |
2013 |
10
๐
|
|
๐
|
Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome).
8 auth.
C. Shovlin,
A. Guttmacher,
E. Buscarini,
M. Faughnan,
R. Hyland,
C. Westermann,
...
A. Kjeldsen,
H. Plauchu
|
10 |
2000 |
10
๐
|
|
๐
|
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
25 auth.
K. Kowdley,
S. Gordon,
K. Reddy,
L. Rossaro,
D. Bernstein,
E. Lawitz,
M. Shiffman,
E. Schiff,
R. Ghalib,
M. Ryan,
V. Rustgi,
M. Chojkier,
R. Herring,
A. D. Di Bisceglie,
P. Pockros,
...
G. Subramanian,
D. An,
E. Svarovskaia,
R. Hyland,
P. Pang,
W. Symonds,
J. Mchutchison,
A. Muir,
D. Pound,
M. Fried
|
10 |
2014 |
10
๐
|
|
๐
|
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
26 auth.
J. Goldman,
D. Lye,
D. Hui,
K. Marks,
R. Bruno,
Rocio Montejano,
C. Spinner,
M. Galli,
M. Ahn,
R. Nahass,
Y. Chen,
Devi SenGupta,
R. Hyland,
A. Osinusi,
H. Cao,
...
C. Blair,
Xuelian Wei,
A. Gaggar,
D. Brainard,
W. Towner,
J. Muรฑoz,
K. Mullane,
F. Marty,
K. Tashima,
G. Diaz,
A. Subramanian
|
10 |
2020 |
10
๐
|
|
๐
|
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
30 auth.
C. Spinner,
R. Gottlieb,
G. Criner,
J. R. Arribas Lรณpez,
A. Cattelan,
A. Soriano Viladomiu,
O. Ogbuagu,
P. Malhotra,
K. Mullane,
A. Castagna,
L. Chai,
M. Roestenberg,
O. Tsang,
E. Bernasconi,
Paul Le Turnier,
...
Shan-Chwen Chang,
Devi SenGupta,
R. Hyland,
A. Osinusi,
H. Cao,
C. Blair,
Hongyuan Wang,
A. Gaggar,
D. Brainard,
M. Mcphail,
S. Bhagani,
M. Ahn,
A. Sanyal,
G. Huhn,
F. Marty
|
10 |
2020 |
10
๐
|
|
๐
|
International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia
33 auth.
M. Faughnan,
V. Palda,
G. GarciaโTsao,
U. Geisthoff,
J. McDonald,
D. Proctor,
J. Spears,
Dale H. Brown,
E. Buscarini,
M. Chesnutt,
V. Cottin,
A. Ganguly,
J. Gossage,
A. Guttmacher,
R. Hyland,
...
S. Kennedy,
J. Korzenik,
J. Mager,
A. Ozanne,
J. Piccirillo,
D. Picus,
H. Plauchu,
M. Porteous,
R. Pyeritz,
D. Ross,
C. Sabbร ,
K. Swanson,
Peter B. Terry,
M. Wallace,
C. Westermann,
R. White,
L. Young,
R. Zarrabeitia
|
9 |
2009 |
9
๐
|
|
๐
|
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
30 auth.
R. Gottlieb,
C. E. Vaca,
R. Paredes,
J. Mera,
B. Webb,
Gilberto Pรฉrez,
Godson Oguchi,
P. Ryan,
B. Nielsen,
M. Brown,
Ausberto Hidalgo,
Yessica Sachdeva,
S. Mittal,
O. Osiyemi,
J. Skarbinski,
...
K. Juneja,
R. Hyland,
A. Osinusi,
Shuguang Chen,
G. Camus,
Mazin Abdelghany,
Santosh Davies,
Nicole Behenna-Renton,
F. Duff,
F. Marty,
Morgan J. Katz,
A. Ginde,
Sam Brown,
Joshua T. Schiffer,
Joshua A. Hill
|
9 |
2021 |
9
๐
|
|
๐
|
Sofosbuvir and ribavirin in HCV genotypes 2 and 3.
17 auth.
S. Zeuzem,
G. Dusheiko,
R. Salupere,
A. Mangia,
R. Flisiak,
R. Hyland,
A. Illeperuma,
E. Svarovskaia,
D. Brainard,
W. Symonds,
...
G. Subramanian,
J. Mchutchison,
O. Weiland,
H. Reesink,
P. Ferenci,
C. Hรฉzode,
R. Esteban
|
9 |
2014 |
9
๐
|
|
๐
|
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.
8 auth.
E. Gane,
C. Stedman,
R. Hyland,
Xiao Ding,
E. Svarovskaia,
W. Symonds,
...
R. Hindes,
M. Berrey
|
9 |
2013 |
9
๐
|
|
๐ข
|
Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group.
L. Mandell,
T. Marrie,
R. Grossman,
A. Chow,
R. Hyland
|
9 |
2000 |
9
๐ข
|
|
๐
|
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
33 auth.
H. Ford,
M. Bourliere,
S. Gordon,
S. Flamm,
C. Cooper,
A. Ramji,
M. Tong,
N. Ravendhran,
J. Vierling,
T. Tran,
S. Pianko,
M. Bansal,
V. Ledinghen,
R. Hyland,
L. Stamm,
...
H. DvoryโSobol,
E. Svarovskaia,
Jie Zhang,
K. C. Huang,
G. Subramanian,
D. Brainard,
J. Mchutchison,
E. Verna,
P. Buggisch,
C. Landis,
Z. Younes,
M. Curry,
S. Strasser,
E. Schiff,
K. Reddy,
M. Manns,
K. Kowdley,
S. Zeuzem
|
9 |
2017 |
9
๐
|
|
๐
|
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
9 auth.
E. Lawitz,
F. Poordad,
P. Pang,
R. Hyland,
Xiao Ding,
H. Mo,
...
W. Symonds,
J. Mchutchison,
F. Membreno
|
9 |
2014 |
9
๐
|
|
๐
|
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
30 auth.
Ira M. Jacobson,
E. Lawitz,
E. Gane,
B. Willems,
P. Ruane,
R. Nahass,
S. Borgia,
S. Shafran,
K. Workowski,
Brian L. Pearlman,
R. Hyland,
L. Stamm,
E. Svarovskaia,
H. DvoryโSobol,
Yanni Zhu,
...
G. Subramanian,
D. Brainard,
J. Mchutchison,
N. Brรคu,
T. Berg,
K. Agarwal,
B. Bhandari,
Mitchell N. Davis,
J. Feld,
G. Dore,
C. Stedman,
A. Thompson,
T. Asselah,
S. Roberts,
G. Foster
|
8 |
2017 |
8
๐
|
